retatrutide in australia Research Guide: What the Phase 2 Trial Data Reported (2026) When Will Retatrutide Be Available

53(6):274 to 278

Molecular Identity Developer Eli Lilly Mechanism Triple GLP-1, GIP, and glucagon receptor agonist FDA Status Under regulatory review (Phase 3 complete) Administration Weekly subcutaneous Triple-Agonist Mechanism Retatrutide combines all pathways: GLP-1: Core incretin signaling (shared with both Mazdutide and Tirzepatide) GIP: Second incretin pathway (shared with Tirzepatide, absent in Mazdutide) Glucagon: Hepatic energy expenditure (shared with Mazdutide, absent in Tirzepatide) For research examining the contributions of all three pathways, Retatrutide provides comprehensive coverage

This does not always mean something is wrong

Very happy with my situation. K.G.G., Facebook Anxiety and Depression Worsened With GLP-1s My anxiety has worsened quite a bit since starting Ozempic